PMID- 34724715
OWN - NLM
STAT- MEDLINE
DCOM- 20220406
LR  - 20240404
IS  - 2157-6580 (Electronic)
IS  - 2157-6564 (Print)
IS  - 2157-6564 (Linking)
VI  - 10 Suppl 2
IP  - Suppl 2
DP  - 2021 Nov
TI  - CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics 
      for all patients.
PG  - S10-S17
LID - 10.1002/sctm.21-0135 [doi]
AB  - Clinical success of adoptive cell therapy with chimeric antigen receptor (CAR) T 
      cells for treating hematological malignancies has revolutionized the field of 
      cellular immunotherapy. However, due to the nature of utilizing autologous T 
      cells, affordability and availability are major hurdles, in addition to 
      scientific challenges relating to CAR-T therapy optimization. Natural killer (NK) 
      cell is a specialized immune effector cell type that recognizes and kills targets 
      without human leukocyte antigen (HLA) restriction and prior sensitization. CAR-NK 
      cells do not cause graft vs host disease and can be obtained from unrelated 
      donors as well as pluripotent stem cells (PSC), representing an ideal 
      off-the-shelf therapeutics readily available for patients. Furthermore, unlike 
      cytotoxic T cells, NK cells specifically target and eliminate cancer stem cells, 
      which are the cells causing relapse and metastasis. PSCs can be genetically 
      manipulated and engineered with CARs at the pluripotent stage, which allows the 
      establishment of permanent, stable, and clonal PSC-CAR lines for the manufacture 
      of unlimited homogenous CAR-NK cells. Multiple master PSC-CAR cell banks 
      targeting a variety of antigens for cancer, viral infection, and autoimmune 
      diseases provide inexhaustible cell sources for all patients. Development of a 
      next-generation 3D bioreactor platform for PSC expansion and NK cell production 
      overcomes major barriers related to cost and scalability for CAR-NK product.
CI  - (c) 2021 Hebecell Corp. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley 
      Periodicals LLC on behalf of AlphaMed Press.
FAU - Lu, Shi-Jiang
AU  - Lu SJ
AD  - HebeCell Corporation, Natick, Massachusetts, USA.
FAU - Feng, Qiang
AU  - Feng Q
AD  - HebeCell Corporation, Natick, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Stem Cells Transl Med
JT  - Stem cells translational medicine
JID - 101578022
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Killer Cells, Natural
MH  - *Neoplasms/therapy
MH  - *Pluripotent Stem Cells/metabolism
MH  - *Receptors, Chimeric Antigen/genetics/metabolism
PMC - PMC8560199
OTO - NOTNLM
OT  - CAR-NK
OT  - CAR-T
OT  - cellular immunotherapy
OT  - off-the-shelf therapeutics
OT  - pluripotent stem cells
COIS- S.J.L. is the co-founder and chief executive officer and Q.F. is the co-founder 
      and chief scientific officer of HebeCell Corporation. Both S.J.L. and Q.F. 
      declare employment and stock ownership at HebeCell Corporation.
EDAT- 2021/11/02 06:00
MHDA- 2022/04/07 06:00
PMCR- 2021/11/01
CRDT- 2021/11/01 20:05
PHST- 2021/05/04 00:00 [revised]
PHST- 2021/04/09 00:00 [received]
PHST- 2021/05/16 00:00 [accepted]
PHST- 2021/11/01 20:05 [entrez]
PHST- 2021/11/02 06:00 [pubmed]
PHST- 2022/04/07 06:00 [medline]
PHST- 2021/11/01 00:00 [pmc-release]
AID - SCT312976 [pii]
AID - 10.1002/sctm.21-0135 [doi]
PST - ppublish
SO  - Stem Cells Transl Med. 2021 Nov;10 Suppl 2(Suppl 2):S10-S17. doi: 
      10.1002/sctm.21-0135.